Skip to content

Clinical Application and Mechanism Study of Moxibustion on Immune Function Regulation of Patients with Esophageal Carcinoma of Deficiency of Qi

Clinical Application and Mechanism Study of Moxibustion on Immune Function Regulation of Patients with Esophageal Carcinoma of Deficiency of Qi

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2000003275
Enrollment
Unknown
Registered
2020-05-04
Start date
2020-05-01
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Esophageal cancer

Interventions

Sponsors

Henan Province Hospital of TCM
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: a. Age: 18 to 75 years old (>=18 years old, = 60 points; f. The expected survival time is >= 3 months, the main organs are in good function, and the blood routine test standards must be met (without blood transfusion and blood products within 14 days, without using G-CSF and other hematopoietic stimulating factors to correct): HB >= 90 g / L; WBC >= 3.5 x 10^9 / L; ANC >= 1.5 x 10^9 / L; PLT >= 80 x 10^9 / L. . g. Patients with voluntary consent and good compliance with the informed consent; h. Female subjects must take effective contraceptive measures throughout the study period; during screening and throughout the study period, serum or urine pregnancy test results must be negative; male subjects should be within the period of acceptance and within 1 month after completion of chemotherapy Take effective contraception.

Exclusion criteria

Exclusion criteria: a. Patients with diabetes, cardiovascular, cerebrovascular, liver, kidney, and hematopoietic system or other serious diseases; b. Patients with contagious infectious diseases; c. There are contraindications for supervised moxibustion, such as joint deformities, unfavorable movement, disabled allergy for those who cannot prone for a long time, skin surface near the superficial veins that has not healed, or bleeding after injury is unknown; d. According to the investigator's judgment, there are concomitant diseases that seriously endanger the patient's safety or affect the patient's completion of the study.

Design outcomes

Primary

MeasureTime frame
KPS score;Bone marrow suppression;T lymphocyte subsets;Cancer patient quality of life assessment form;Serum immunoglobulin;

Secondary

MeasureTime frame
PFS;Piper fatigue survey scale;TCM Syndrome Points Scale;

Countries

China

Contacts

Public ContactYuping Wang

Henan Province Hospital of TCM

13838205267@163.com+86 13838205267

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026